Genetic and Epigenetic Interplay in Cancer Session at TCEC 2013

[Pavolga]

Recent discoveries from the sequencing of various types of human cancers have revealed a remarkable amount of aberrantly expressed and mutated epigenetic-specific genes. The combination of known genetic contributors with a largely undefined epigenetic regulatory layer provides a clearer picture as to the complexity of factors initiating and driving the progression of cancers. This session of TCEC: The Clinical Epigenome Conference features presentations highlighting how cancer epigenomes influence the underlying genome, and vice versa, with this interplay working to produce disease outcomes.

View meeting agenda: http://www.clinicalgenomeconference....ical-Epigenome

Registration information: https://chidb.com/register/2013/clg/reg.asp (Early registration discount of up to $350 ends on March 29)

FEATURED SESSION: GENETIC & EPIGENETIC INTERPLAY IN CANCER

» KEYNOTE PRESENTATION
Spontaneous and Therapy Induced Evolution of Tumor Genomes and Epigenomes
Joseph Costello, Ph.D., Professor in Residence, Department of Neurological Surgery; Director, Epigenetics Division, Cell Cycling and Signaling Program, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco

Distinguishing between Driver and Passenger Epigenetic Modifications in Cancer
Daniel De Carvalho, Ph.D., Principal Investigator, Ontario Cancer Institute, University Health Network; Assistant Professor, Medical Biophysics, Faculty of Medicine, University of Toronto

Constitutional BRCA1 Methylation and Cancer Predisposition
Alexander Dobrovic, Ph.D., Head, Molecular Pathology Research & Development, Peter McCallum Cancer Centre

» OTHER CONFERENCE TOPICS INCLUDE:

- Mechanisms in (De)Methylation Underlying Development of Disease
- The Predictive Power of Epigenetics: Diagnostic & Prognostic Utility
- The Clinical Genome Technology Showcase
- Trends in Analysis & Interpretation